Vision therapy helps brain injury patients

Article

Stroke and traumatic brain injury survivors, who have undergone vision restoration therapy (VRT), demonstrate increased brain activity, according to researchers from Columbia University Medical Center, USA.

Stroke and traumatic brain injury survivors, who have undergone vision restoration therapy (VRT), demonstrate increased brain activity, according to researchers from Columbia University Medical Center, USA.

Randolph Marshall and colleagues examined the functional magnetic resonance imaging (fMRIs) of six patients aged between 35 and 77 with homonymous hemianopia vision loss caused by stroke or traumatic brain injury. Each patient underwent VRT therapy to help rehabilitate their vision.

The fMRI data showed that there was an increased activity in the visual processing areas of the brain as patients learned to detect stimuli in the border zone between the seeing and non-seeing fields. This enhanced activity was identified one month after the start of treatment, suggesting that the brain responds accordingly.

The treatment involves patients performing daily therapy at home for between six and seven months, gradually improving their vision through repeated detection of light stimuli directed at the border between the seeing and blind areas of the visual field.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.